MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
2022 · Cancer Cell · 199 citations
https://doi.org/10.1016/j.ccell.2021.12.009
L
Laure Favier
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
173
Papers
2.8K
Citations
25
h-index
42
i10-index
Laure Favier is an academic researcher from Centre Georges François Leclerc. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & PARP inhibition in cancer therapy & BRCA gene mutations in cancer. The author has an h-index of 25, co-authored 148 publications.
Papers by this author
worksVemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
2020 · Annals of Oncology · 187 citations
https://doi.org/10.1016/j.annonc.2019.10.022
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
2013 · British Journal of Cancer · 102 citations
https://doi.org/10.1038/bjc.2013.183
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
2010 · British Journal of Cancer · 45 citations
https://doi.org/10.1038/sj.bjc.6605939
Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study
2012 · The Breast · 24 citations
https://doi.org/10.1016/j.breast.2012.07.012
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
2012 · British Journal of Cancer · 22 citations
https://doi.org/10.1038/bjc.2012.304
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat